218 related articles for article (PubMed ID: 24092664)
21. Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis.
Lavie M; Struyf S; Stroh-Dege A; Rommelaere J; Van Damme J; Dinsart C
Virology; 2013 Dec; 447(1-2):221-32. PubMed ID: 24210118
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.
Ferreira T; Kulkarni A; Bretscher C; Richter K; Ehrlich M; Marchini A
Viruses; 2020 Oct; 12(10):. PubMed ID: 33096814
[TBL] [Abstract][Full Text] [Related]
23. Enhanced antitumor activity of combined methotrexate and histone deacetylase inhibitor valproic acid on mammary cancer in vitro and in vivo.
El Said HH; Badary OA; Shouman SA; Elmazar MM; El-Khatib AS
Can J Physiol Pharmacol; 2022 Sep; 100(9):915-925. PubMed ID: 35679619
[TBL] [Abstract][Full Text] [Related]
24. Double-faceted mechanism of parvoviral oncosuppression.
Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
[TBL] [Abstract][Full Text] [Related]
25. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo.
Sami S; Höti N; Xu HM; Shen Z; Huang X
J Biochem; 2008 Sep; 144(3):357-62. PubMed ID: 18515856
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
[TBL] [Abstract][Full Text] [Related]
27. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C; Marchini A
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
[TBL] [Abstract][Full Text] [Related]
28. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
[TBL] [Abstract][Full Text] [Related]
29. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.
Alvarez-Breckenridge CA; Yu J; Price R; Wei M; Wang Y; Nowicki MO; Ha YP; Bergin S; Hwang C; Fernandez SA; Kaur B; Caligiuri MA; Chiocca EA
J Virol; 2012 Apr; 86(8):4566-77. PubMed ID: 22318143
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
32. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
[TBL] [Abstract][Full Text] [Related]
33. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
[TBL] [Abstract][Full Text] [Related]
34. [Oncolytic parvoviruses. A new approaches for cancer therapy].
Loktev VB; Ivan'kina TIu; Netesov SV; Chumakov PM
Vestn Ross Akad Med Nauk; 2012; (2):42-7. PubMed ID: 22642177
[TBL] [Abstract][Full Text] [Related]
35. Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species.
Hristov G; Krämer M; Li J; El-Andaloussi N; Mora R; Daeffler L; Zentgraf H; Rommelaere J; Marchini A
J Virol; 2010 Jun; 84(12):5909-22. PubMed ID: 20375165
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
[TBL] [Abstract][Full Text] [Related]
37. Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.
Frehtman V; Wohlfarth D; Müller M; Krebs O; Leuchs B
Appl Microbiol Biotechnol; 2023 Aug; 107(15):4777-4787. PubMed ID: 37209160
[TBL] [Abstract][Full Text] [Related]
38. In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line.
Sanaei M; Kavoosi F; Roustazadeh A; Shahsavani H
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2507-2510. PubMed ID: 30256044
[TBL] [Abstract][Full Text] [Related]
39. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
Akladios C; Aprahamian M
Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
[TBL] [Abstract][Full Text] [Related]
40. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]